Previous 10 | Next 10 |
Provention Bio (NASDAQ: PRVB ) +1% prices its public offering of 6.6M common shares at $14.50 per share for gross proceeds of $95.7M. More news on: Provention Bio, Inc., Healthcare stocks news, , Read more ...
OLDWICK, N.J. , June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of it...
Shares of Provention Bio (NASDAQ: PRVB) , a clinical-stage biotech company, fell by about 7% on Wednesday, following the company's announcement that it would initiate a public offering of common stock. Provention Bio made this announcement on Tuesday afternoon. Naturally, investors aren't too...
Gainers: INWK +46.6% . FLGT +9.3% . GRPN +4.7% . STWD +4.6% . MG +4.2% . More news on: InnerWorkings, Inc., Fulgent Genetics, Inc., Groupon, Inc., Stocks on the move, , Read more ...
Shares of Proventio Bio (NASDAQ: PRVB) -- a clinical-stage biotech company -- jumped by 9.4% on Monday after the drugmaker reported positive data from a clinical trial for one of its lead pipeline candidates, teplizumab (PRV-031). Proventio Bio has big ambitions: The company is lookin...
Provention Bio ( PRVB +10.6% ) is up on a 4x surge in volume in reaction to follow-up data from a Phase 2 study, "At Risk" TN-10 , evaluating teplizumab for preventing/delaying the onset of type 1 diabetes (T1D) in relatives of type 1 diabetics deemed "at very high risk" of developing t...
OLDWICK, N.J. , June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly del...
OLDWICK, N.J. , May 28, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies Virtual Healthcare Conference on Thursda...
OLDWICK, N.J. , May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced two changes to its board of directors. Nancy Wysenski has been a...
OLDWICK, N.J. and TAMPERE, Finland , May 18, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish biotechnology compan...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...